Ampio Pharmaceuticals, Inc. (AMPE)
| Market Cap | 299.53K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.38M |
| Shares Out | 832.02K |
| EPS (ttm) | -11.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,022 |
| Open | 0.320 |
| Previous Close | 0.286 |
| Day's Range | 0.285 - 0.360 |
| 52-Week Range | 0.220 - 8.200 |
| Beta | 1.95 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2024 |
About AMPE
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado. [Read more]
Financial Performance
Financial StatementsNews
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form ...
Ampio Announces Voluntary Delisting and SEC Deregistration
ENGLEWOOD, Colo. , March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily del...
Ampio Provides Update on Results from Pre-IND Enabling Studies
ENGLEWOOD, Colo. , Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a...
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions
ENGLEWOOD, Colo. , Jan. 11, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a...
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
ENGLEWOOD, Colo. , Oct. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential t...
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201
ENGLEWOOD, Colo. , Oct. 5, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential tr...
Ampio Pharmaceuticals Announces Reverse Stock Split
ENGLEWOOD, Colo. , Aug. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors has approved a 20-to-1 reverse stock spli...
Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock
ENGLEWOOD, Colo. , May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth ...
AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS
ENGLEWOOD, Colo. , April 18, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi a...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ampio Pharmaceuticals, Inc.
Wilmington, Delaware--(Newsfile Corp. - February 7, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE) on beha...
Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
ENGLEWOOD, Colo. , Dec. 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE A...
Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension
ENGLEWOOD, Colo. , Nov. 17, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE) (the "Company") received notification from NYSE American LLC ("NYSE American" or the "Exchan...
Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split
Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), announced today that effective November 9, 2022 at 4:01 p.m. Eastern Time, the Company will amend its certificate of incorporation to implem...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Ampio Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2022 - (NYSE: AMPE)
NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ampio Pharmaceuticals, Inc.. Shareholders who purchased shares of AMPE during the class perio...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuti...
AMPE DEADLINE TODAY: ROSEN, A TOP RANKED FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPE
New York, New York--(Newsfile Corp. - October 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (OTC Pink: AMPE) b...
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 17, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("...
Ampio Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 17, 2022 to Discuss Your Rights - AMPE
New York, New York--(Newsfile Corp. - October 16, 2022) - Levi & Korsinsky, LLP notifies investors in Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) of a class action securities l...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ampio Pharmaceuticals, Inc. - AMPE
New York, New York--(Newsfile Corp. - October 16, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE) ("Ampio" or the "Company"). Such inve...
AMPE DEADLINE TOMORROW: ROSEN, skilled investor counsel, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPE
NEW YORK , Oct. 16, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (OTC: AMPE) between December 29, 20...
Ampio Pharmaceuticals Issues Letter to Stockholders
Proposal to Authorize Reverse Stock Split has Been Approved ENGLEWOOD, Colo. , Oct. 14, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), today released the following le...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. (AMPE)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R.
MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuti...
AMPE SHAREHOLDER ALERT: Jakubowitz Law Reminds Ampio Shareholders of a Lead Plaintiff Deadline of October 17, 2022
NEW YORK , Oct. 14, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Ampio Pharmaceuticals, Inc. (NYSE: AMPE). To r...
AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES , Oct. 13, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai...